Pharmaron Beijing Co Ltd (300759) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) has a cash flow conversion efficiency ratio of 0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.04 Billion ≈ $151.79 Million USD) by net assets (CN¥15.18 Billion ≈ $2.22 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pharmaron Beijing Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Pharmaron Beijing Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Pharmaron Beijing Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300759 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Pharmaron Beijing Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmaron Beijing Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASM Pacific Technology Limited
F:AY7A
|
N/A |
|
The Magnum Ice Cream Company N.V.
AS:MICC
|
0.153x |
|
Tetra Tech Inc
NASDAQ:TTEK
|
0.089x |
|
Corporacion Acciona Energias Renovables SA
MC:ANE
|
0.011x |
|
Turkiye Is Bankasi AS Class C
IS:ISCTR
|
0.220x |
|
Ternium S.A
F:T5Z
|
0.013x |
|
Oil India Limited
NSE:OIL
|
0.054x |
|
AptarGroup Inc
NYSE:ATR
|
0.044x |
Annual Cash Flow Conversion Efficiency for Pharmaron Beijing Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Pharmaron Beijing Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Pharmaron Beijing Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥14.22 Billion ≈ $2.08 Billion |
CN¥2.58 Billion ≈ $377.05 Million |
0.181x | -12.90% |
| 2023-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
CN¥2.75 Billion ≈ $402.93 Million |
0.208x | +5.22% |
| 2022-12-31 | CN¥10.84 Billion ≈ $1.59 Billion |
CN¥2.14 Billion ≈ $313.56 Million |
0.198x | -1.11% |
| 2021-12-31 | CN¥10.30 Billion ≈ $1.51 Billion |
CN¥2.06 Billion ≈ $301.16 Million |
0.200x | +8.33% |
| 2020-12-31 | CN¥8.93 Billion ≈ $1.31 Billion |
CN¥1.65 Billion ≈ $241.24 Million |
0.185x | +54.10% |
| 2019-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
CN¥938.59 Million ≈ $137.34 Million |
0.120x | -61.96% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.70 Million |
CN¥737.26 Million ≈ $107.88 Million |
0.315x | +14.60% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.17 Million |
CN¥552.22 Million ≈ $80.81 Million |
0.275x | +105.46% |
| 2016-12-31 | CN¥1.76 Billion ≈ $258.04 Million |
CN¥235.77 Million ≈ $34.50 Million |
0.134x | -89.62% |
| 2015-12-31 | CN¥168.43 Million ≈ $24.65 Million |
CN¥216.94 Million ≈ $31.75 Million |
1.288x | +2641.07% |
| 2014-12-31 | CN¥258.25 Million ≈ $37.79 Million |
CN¥12.13 Million ≈ $1.78 Million |
0.047x | -- |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more